Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.
about
Herbal medicines for treating HIV infection and AIDSThe use of herbal medicines in early drug development for the treatment of HIV infections and AIDSHuman immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice.Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones.Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activityCellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Antibiotic adjuvants: multicomponent anti-infective strategies.Nutrition and the HIV-associated lipodystrophy syndrome.Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone.Lack of evidence for in vivo transformation of zidovudine triphosphate to stavudine triphosphate in human immunodeficiency virus-infected patients.Rapid identification of efavirenz metabolites in rats and humans by ultra high performance liquid chromatography combined with quadrupole time-of-flight tandem mass spectrometry.Suppressive drug combinations and their potential to combat antibiotic resistance.The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients.The impact of neuropsychological impairment and depression on health-related quality of life in HIV-infection.3D-QSAR studies of quinoline ring derivatives as HIV-1 integrase inhibitors.Exploring direction of causation between social support and clinical outcome for HIV-positive adults in the context of highly active antiretroviral therapyPrevalence and patterns of higher-order drug interactions in
P2860
Q24246643-106DB4D6-D73B-4CA6-B63E-0C4699B409B0Q28241719-FD39B35F-D351-4D27-9E74-7F00F3954DB0Q33987492-90ACF253-D261-4CCA-9FFF-EAB6C327AC11Q34141998-C20BE5CF-AC3F-4986-9739-D4DF0A28695FQ34307103-C7BD7D71-F692-4888-8DF2-1C4FAACB713BQ34734416-1D5D2860-E5F5-4A22-A4A0-B9C8CFD3651BQ36011828-743671E5-CD42-4034-BD98-C5933D79EFC1Q37845955-867D12E4-8AFC-4F5B-9378-733CC6315336Q38061798-13EC2AD5-0C68-4785-A3FB-B708E31F74CDQ39537216-1A47FDEC-4EC4-4916-943A-BE9055EED6A7Q39881130-BE0A19F3-3A62-4161-B04A-57A44062C727Q40312836-FE8BC9CD-9C17-45CE-8083-F2A70901E95DQ41365021-7D117D70-08BF-47C8-B21B-3A1E5FB1F479Q42612662-0F72A7F0-036B-4200-90A8-521EC59299D5Q44787744-0D4A92FF-31BE-40DA-8B81-F98FCEFB6E09Q51931408-FCCA5C63-BF5C-4650-A003-289C5B6ED0ACQ54482597-AEED368D-E7CA-4A0A-AC30-6D863058B1BFQ58266097-1327FCA7-08C0-41EE-911E-0D28405372B6Q58769710-5C2B45A2-DFFC-4F0B-8A2A-90B43AC5C341
P2860
Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Highly active antiretroviral t ...... immunodeficiency virus type 1.
@ast
Highly active antiretroviral t ...... immunodeficiency virus type 1.
@en
type
label
Highly active antiretroviral t ...... immunodeficiency virus type 1.
@ast
Highly active antiretroviral t ...... immunodeficiency virus type 1.
@en
prefLabel
Highly active antiretroviral t ...... immunodeficiency virus type 1.
@ast
Highly active antiretroviral t ...... immunodeficiency virus type 1.
@en
P1476
Highly active antiretroviral t ...... immunodeficiency virus type 1.
@en
P2093
P356
10.1016/S0753-3322(99)80063-8
P577
1999-03-01T00:00:00Z